Viking's Q1 earnings show no revenue, increased R&D spending, and a substantial cash reserve, positioning it well for future ...

Viking Therapeutics, Inc. ("Viking") , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial ...

Lilly trumpeted positive topline results from ACHIEVE-1 (NCT05971940) showing orforglipron to have met the trial’s primary ...

Discover why VKTX's deep selloff offers a compelling opportunity with improved safety margins, promising GLP-1 candidates, ...

Shares of Viking Therapeutics have sold off sharply as the market awaits updates on its drug candidates. The company is ...

While the company has not yet launched a product, its VK2735 candidate -- a dual agonist targeting glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP ...

Pfizer ends danuglipron development after liver safety issue, boosting shares of Viking, Eli Lilly, and Novo Nordisk amid ...

Fasting C-peptide (FCP) shows a nonlinear relationship with diabetic retinopathy (DR) risk, with a protective effect below 4.11 ng/mL. Above 4.11 ng/mL, the protective effect of FCP on DR becomes ...

The firm’s analysis pointed to the competitive nature of the obesity treatment market as a significant challenge for Viking’s lead asset, VK2735. The therapy, a dual GLP-1/GIP agonist, has shown ...